evidence across a significant variety of studies to indicate that fQRS is a predictor of future major adverse cardiac events (MACE) (including arrhythmic events)/mortality/poor prognosis in patients with known coronary artery disease (CAD)/ acute coronary syndromes, left ventricular dysfunction, cardiomyopathy, and Brugada syndrome. There is less evidence (but some) of this in suspected CAD, acquired QT prolongation, sarcoidosis, amyloidosis and arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).